Regeneron Pharmaceuticals Inc. ; est. no. 1760

Tarrytown, NY; received FDA approval in Dec. 1999 as a contract manufacturer for an undisclosed intermediate for a marketed vaccine from Merck & Co. and was expected to receive $50 million from Merck over 6 years